Red Orbit (Free subscription) | 04/09/2008
Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that the United States Food and Drug Administration (FDA) has accepted the Company's abbreviated new drug application (ANDA) for a generic formulation of 145mg and 48mg strengths of fenofibrate tablets (sold under the brand name Tricor by Abbott Laboratories).
Red Orbit (Free subscription) | 25/08/2008
Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that it has received an expanded indication for once-daily Ralivia(TM) - to include the treatment of moderately severe pain in addition to moderate pain - from the Therapeutic Products Directorate (TPD) in Canada.
Business Wire (Free subscription) | 25/08/2008
TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that it has received an expanded indication for once-daily Ralivia™
CFO (Free subscription) | 21/08/2008
The Canadian drugmaker, facing SEC revenue-reporting violations, hires a veteran with banking-finance and "game theory" experience.
Red Orbit (Free subscription) | 21/08/2008
Biovail Corporation has appointed Neil Sussman as vice president of neurologic and psychiatric development of Biovail Technologies. Dr Sussman brings a wealth of business and academic experience in the field of neurology and other central nervous system (CNS) disorders to Biovail.
Business Wire (Free subscription) | 21/08/2008
TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced the appointment of Peggy Mulligan, FCA as Chief Financial Officer, effective September 3, 2008. Mrs.
Seeking Alpha (Free subscription) | 14/08/2008
FP Trading Desk submits: RBC Capital Markets analyst Doug Miehm offered qualified support for drug maker Biovail Corp.'s (BVF) much talked about strategic shift into central nervous system drugs, praising management in a note this morning for doing "a good job" of explaining the new focus. However, in a note to clients Mr. Miehm went on to say he believes the company faces significant risk in implementation....
Market Wire - Investment Opinion (Free subscription) | 14/08/2008
LONDON (MARKET WIRE) MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Through our numerous partnerships with many of the top investment minds in the world, we provide research on companies making a move in the markets. Investors seeking genuine analyst opinions on their investments for Grande Cache Coal Corporation (TSX: GCE), Talisman Energy...
atHome Top Story (Free subscription) | 14/08/2008
The cost of shutting down manufacturing plants in Puerto Rico and a research and development facility in Ireland pushed drug maker Biovail Corp. into a quarterly loss, but the company said yesterday it is still looking for acquisitions.
Market Watch (Free subscription) | 13/08/2008
Drug stocks inch higher in early activity while shares of Biovail Corp. lose ground after the drugmaker reports a second-quarter loss due in part to lower sales.
Market Watch (Free subscription) | 13/08/2008
BOSTON (MarketWatch) -- Drug stocks inched higher early Wednesday while shares of Biovail Corp. lost ground after it reported a second-quarter loss due in part to lower sales. The Amex Pharmaceutical Index and the Amex Biotechnology Index were both up nominally at 316.3 and 873.7, respectively. Shares of Biovail were down 4% at $9.56. The drugmaker also said it sees a continued decline in product...
atHome Top Story (Free subscription) | 13/08/2008
Biovail Corp. had a US$25.3-million loss in its second quarter as Canada's largest publicly traded drug company suffered from a number of special legal and restructuring charges and a drop in sales revenue.
Market Watch (Free subscription) | 13/08/2008
NEW YORK (MarketWatch) -- Biovail Corp. said Wednesday that it lost $25 million, or 16 cents a share, in the second quarter. In the same period a year ago Biovail earned $68 million, or 42 cents. Revenue fell to $186 million compared with $203 million a year ago. Analysts polled by FactSet, on average, estimated earnings per share of 35 cents on sales of $190 million. Biovail reported a $52 million...
Business Wire (Free subscription) | 13/08/2008
TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced financial results for the three-month and six-month periods ended June 30, 2008. To the extent that this
atHome Top Story (Free subscription) | 09/08/2008
Biovail Corp.'s management now has a mandate to implement its new strategy for growth, said chair Doug Squires, after its nominees for the board of directors were declared elected yesterday.
